1. Home
  2. XLO vs MNDO Comparison

XLO vs MNDO Comparison

Compare XLO & MNDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XLO
  • MNDO
  • Stock Information
  • Founded
  • XLO 2016
  • MNDO 1995
  • Country
  • XLO United States
  • MNDO Israel
  • Employees
  • XLO N/A
  • MNDO N/A
  • Industry
  • XLO Biotechnology: Pharmaceutical Preparations
  • MNDO EDP Services
  • Sector
  • XLO Health Care
  • MNDO Technology
  • Exchange
  • XLO Nasdaq
  • MNDO Nasdaq
  • Market Cap
  • XLO 42.1M
  • MNDO 39.9M
  • IPO Year
  • XLO 2021
  • MNDO 2000
  • Fundamental
  • Price
  • XLO $0.83
  • MNDO $2.12
  • Analyst Decision
  • XLO Buy
  • MNDO
  • Analyst Count
  • XLO 1
  • MNDO 0
  • Target Price
  • XLO $4.00
  • MNDO N/A
  • AVG Volume (30 Days)
  • XLO 592.2K
  • MNDO 30.5K
  • Earning Date
  • XLO 11-07-2024
  • MNDO 03-05-2025
  • Dividend Yield
  • XLO N/A
  • MNDO 11.32%
  • EPS Growth
  • XLO N/A
  • MNDO N/A
  • EPS
  • XLO N/A
  • MNDO 0.23
  • Revenue
  • XLO $4,620,000.00
  • MNDO $21,856,000.00
  • Revenue This Year
  • XLO N/A
  • MNDO N/A
  • Revenue Next Year
  • XLO $368.76
  • MNDO N/A
  • P/E Ratio
  • XLO N/A
  • MNDO $9.18
  • Revenue Growth
  • XLO N/A
  • MNDO 2.27
  • 52 Week Low
  • XLO $0.50
  • MNDO $1.70
  • 52 Week High
  • XLO $1.93
  • MNDO $2.28
  • Technical
  • Relative Strength Index (RSI)
  • XLO 39.23
  • MNDO 74.17
  • Support Level
  • XLO $0.78
  • MNDO $2.02
  • Resistance Level
  • XLO $1.28
  • MNDO $2.04
  • Average True Range (ATR)
  • XLO 0.13
  • MNDO 0.03
  • MACD
  • XLO -0.02
  • MNDO 0.01
  • Stochastic Oscillator
  • XLO 9.94
  • MNDO 96.30

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

About MNDO MIND C.T.I. Ltd.

MIND C.T.I. Ltd develops, manufactures, markets and implements real-time and off-line convergent billing and customer care software solutions. The company derives revenue from sale of software products and services in two operating segments namely Billing and Related Services, which derives key revenue and Messaging. The Company has three product lines: Product line A- billing and customer care solutions for service providers; Product line B - call accounting and call management solutions for enterprises; and Product line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in The Americas, Europe, Asia Pacific and Africa and Israel. It earns maximum revenue from Europe.

Share on Social Networks: